REVA Medical Provides Quarterly Cashflow Report for the Quarter Ended 30 September 2018

San Diego, California and Sydney, Australia (Tuesday, 30 October 2018 - AEDT) – REVA Medical, Inc. (ASX: RVA) ("REVA" or the "Company"), a leader in bioresorbable polymer technologies for vascular medical applications, is pleased to provide the attached Appendix 4C Quarterly Cashflow Report for the quarter ended 30 September 2018. The Appendix 4C is unaudited.

Appendix 4C Summary (all amounts in U.S. dollars)

As of 30 September 2018, the Company's cash balance was $7.1 million which is a decrease of $11.5 million from the 31 December 2017 balance of $18.5 million, and a decrease of $3.0 million from the 30 June 2018 balance.

Our third quarter cash flow activity primarily consisted of $4.0 million in disbursements related to normal operating activities and purchases of $268,000 of capital equipment and leasehold improvements, offset by $735,000 of proceeds from the sale of investment securities, $297,000 in reimbursements for leasehold improvements in accordance with our amended facility lease and $151,000 in cash receipts from customers.

We believe that our cash balance of $7.1 million as of 30 September 2018 will be sufficient to fund our operating and capital needs through the first quarter of 2019, based on our current expense forecast and assuming that we achieve certain minimum levels of sales of our Fantom and Fantom Encore scaffolds between now and the first quarter of 2019. Accordingly, the Company will need to raise further capital to support our commercialization activities, and to conduct additional clinical trials, if we determine to do so. We plan to address our capital needs by pursuing business development and strategic opportunities. We are also evaluating equity or debt financing options.

The Company currently plans to file its Form 10-Q Quarterly Report with the U.S. Securities and Exchange Commission and with the Australian Securities Exchange on or before the due date of 9 November 2018. The Quarterly Report provides financial statements, along with Management's Discussion and Analysis of Financial Condition and Results of Operations for the quarter ended 30 September 2018.

Recent Corporate Highlights

- Fantom Commercial Activities – During the third quarter of 2018, we continued to support sales in Germany, Switzerland, Austria and Turkey. In July 2018, we hired a part-time consultant to support direct sales in Belgium, Luxembourg and the Netherlands and announced our second commercial distribution partnership in Italy. In August 2018, we added a clinical specialist to our team. We recorded $185,000 in product shipments and recognized revenue of $93,000 in the third quarter of 2018. From the second quarter to the third quarter of 2018, our product shipments increased by 24% and our recognized revenue remained consistent. We recognize revenue when we believe that Fantom has been utilized in a surgical procedure and is no longer subject to exchange rights. Additionally, we saw an 18% increase in the total number of customers as of 30 September 2018 versus 30 June 2018.

- New Product Development – In July 2018, we obtained CE Mark for our full Fantom Encore product line. Fantom Encore, like Fantom, is used for the treatment of coronary artery disease ("CAD"). Annually, approximately 5.6 million metallic stents are used to treat CAD and the worldwide sales of stents is estimated to be $4 billion[1]. The Fantom Encore product line has thinner struts than Fantom (95, 105 and 115 microns for the 2.5, 3.0 and 3.5 diameter sizes, respectively, versus 125 microns for all Fantom diameter sizes). Fantom Encore is made with Tyrocore, REVA's proprietary radiopaque bioresorbable polymer. Fantom Encore has the thinnest struts of any commercially available bioresorbable scaffold in Europe. Thin struts are associated with better healing and clinical outcomes. Reduction in strut thickness is considered by physicians to be one of the most important improvements for bioresorbable scaffolds.

- We received CE Mark approval for twelve-month shelf life for Fantom in July 2018 and for Fantom Encore in October 2018. This will enable us to provide extended use-by dates to our customers and will also allow us to begin phasing out our product exchange program during the fourth quarter of 2018. At that time, we also intend to simplify our revenue recognition policy by recognizing revenue upon product shipment and maintaining a reserve against potential future product returns based on historical activity.

- In July 2018, we expanded beyond the coronary arteries into the treatment of below the knee ("BTK") peripheral artery disease ("PAD") with the receipt of CE Mark for the MOTIV bioresorbable scaffold. BTK PAD is a large and growing medical issue. Drug coated balloons and drug eluting metal stents are being used as treatment options. Drug eluting bioresorbable scaffolds present a significant opportunity to improve the treatment of patients suffering from BTK PAD because of the potential to extend drug delivery and to enable retreatment without the risks associated with a metal stent. We estimate that the worldwide market for drug eluting bioresorbable scaffolds in BTK could reach $1.5 billion[2]. We plan to release MOTIV in select centers to assess product performance, inform product development activities and determine commercial strategy. We expect MOTIV's first use in patients to be in late 2018 or early next year.

- We also continue to make progress on a new vascular application, embolics. Embolic beads are used to occlude arteries that feed tumors, such as liver cancer or uterine fibroids. Our technology is uniquely suited to embolic beads because to our knowledge, there are no x-ray visible, bioresorbable embolic products available in the world. Embolic beads are interesting because of established reimbursement, attractive margins, and a relatively straight-forward regulatory path relative to bioresorbable scaffolds. We are currently evaluating a 510k pathway in the United States to take our technology forward for development and commercialization in the embolic bead market.

About Fantom and Fantom Encore

Fantom and Fantom Encore are sirolimus-eluting bioresorbable scaffolds developed as alternatives to metallic stents for the treatment of coronary artery disease. After restoration of blood flow, bioresorbable scaffolds support the artery through the healing process and then disappear (or "resorb") from the body over a period of time. This resorption is intended to allow the return of natural function of the artery and reduce risk of adverse events associated with a permanent metallic implant. Fantom and Fantom Encore are the only bioresorbable scaffolds made from Tyrocore, REVA's proprietary tyrosine-derived polymer designed specifically for vascular scaffold applications. Tyrocore is inherently radiopaque, making Fantom and Fantom Encore the first and only bioresorbable scaffolds that are visible under fluoroscopy. Fantom and Fantom Encore are designed with thin struts while maintaining strength and with distinct ease-of-use features such as x-ray visibility, a large expansion range, expansion with one continuous inflation, and room-temperature storage stability.

[1] JP Morgan Equity Research Interventional Cardiology Market Model Dec. 2016.
[2] Nehler M, et al. Epidemiology of peripheral arterial disease and critical limb ischemia in an insured national population. JVS 2014; Population data from United Nations online database.

About MOTIV

MOTIV is a sirolimus-eluting bioresorbable scaffolds developed for the treatment of below the knee (BTK) peripheral artery disease (PAD). Treatment options for BTK patients are very limited and many patients progress to amputation. MOTIV is intended to expand treatment options to the millions of patients suffering from PAD.

About REVA Medical

REVA Medical is a medical device company focused on the development and commercialization of bioresorbable polymer technologies for vascular applications. The Company's lead products are the Fantom and Fantom Encore bioresorbable vascular scaffolds for the treatment of coronary artery disease. REVA is currently selling Fantom in Germany, Switzerland, Austria, the Netherlands, Belgium, Luxembourg, Italy and Turkey. REVA is based in San Diego, California, and employs more than 50 people in the U.S. and Europe.

Fantom, Fantom Encore, MOTIV, and Tyrocore are trademarks of REVA Medical, Inc.

United States
Investor & Media Enquiries:
REVA Medical, Inc.
Brandi Roberts
Chief Financial Officer
+1 858-966-3003

David Schull
Russo Partners
+1 858-717-2310
david.schull@russopartnersllc.com

Australia
Investor Enquiries:
Perpetuity Capital Pty Ltd
Kim Jacobs
+61 438 217 279
Andrew Cohen
+61 408 333 452

Australia
Media Enquiries:
Buchan Consulting
Rebecca Wilson
+61 3 9866 4722

+Rule 4.7B

Appendix 4C

Quarterly report for entities subject to Listing Rule 4.7B

Introduced 31/03/00 Amended 30/09/01, 24/10/05, 17/12/10, 01/09/16

Name of entity

REVA Medical, Inc.

ABN	**Quarter ended ("current quarter")**
ARBN 146 505 777	30 September 2018

Consolidated statement of cash flows		**Current quarter (Q3) $'000 USD**	**Year to date (9 months) $'000 USD**
1.	**Cash flows from operating activities**		
1.1	Receipts from customers	151	433
1.2	Payments for		
	(a) research and development	(734)	(2,383)
	(b) product manufacturing and operating costs	(468)	(1,399)
	(c) advertising and marketing	(44)	(230)
	(d) leased assets	—	—
	(e) staff costs	(2,178)	(7,176)
	(f) administration and corporate costs	(561)	(2,288)
1.3	Dividends received (see note 3)	—	—
1.4	Interest received	25	72
1.5	Interest and other costs of finance paid	—	—
1.6	Income taxes paid	—	—
1.7	Government grants and tax incentives	—	—
1.8	Other (provide details if material)	297	821
1.9	**Net cash from / (used in) operating activities**	**(3,512)**	**(12,150)**

2.	**Cash flows from investing activities**		
2.1	Payments to acquire:		
	(a) property, plant and equipment	(268)	(820)
	(b) businesses (see item 10)	—	—
	(c) investments	—	—
	(d) intellectual property	—	—
	(e) other non-current assets	—	—

Consolidated statement of cash flows		**Current quarter (Q3) $'000 USD**	**Year to date (9 months) $'000 USD**
2.2	Proceeds from disposal of:		
	(a) property, plant and equipment	—	50
	(b) businesses (see item 10)	—	—
	(c) investments	735	1,470
	(d) intellectual property	—	—
	(e) other non-current assets	—	—
2.3	Cash flows from loans to other entities	—	—
2.4	Dividends received (see note 3)	—	—
2.5	Other (provide details if material)	—	—
2.6	**Net cash from / (used in) investing activities**	**467**	**700**

3.	**Cash flows from financing activities**		
3.1	Proceeds from issues of shares	—	—
3.2	Proceeds from issue of convertible notes	—	—
3.3	Proceeds from exercise of share options	—	—
3.4	Transaction costs related to issues of shares, convertible notes or options	—	—
3.5	Proceeds from borrowings	—	—
3.6	Repayment of borrowings	—	—
3.7	Transaction costs related to loans and borrowings	—	—
3.8	Dividends paid	—	—
3.9	Other	—	—
3.10	**Net cash from / (used in) financing activities**	**—**	**—**

4.	**Net increase / (decrease) in cash and cash equivalents for the period**		
4.1	Cash and cash equivalents at beginning of quarter/year to date	10,139	18,544
4.2	Net cash from / (used in) operating activities (item 1.9 above)	(3,512)	(12,150)
4.3	Net cash from / (used in) investing activities (item 2.6 above)	467	700
4.4	Net cash from / (used in) financing activities (item 3.10 above)	—	—
4.5	Effect of movement in exchange rates on cash held	—	—
4.6	**Cash and cash equivalents at end of quarter**	**7,094**	**7,094**

5.	**Reconciliation of cash and cash equivalents** at the end of the quarter (as shown in the consolidated statement of cash flows) to the related items in the accounts	**Current quarter $'000 USD**	**Previous quarter $'000 USD**
5.1	Bank balances	6,944	9,989
5.2	Call deposits	150	150
5.3	Bank overdrafts	—	—
5.4	Other (provide details)	—	—
5.5	**Cash and cash equivalents at end of quarter (should equal item 4.6 above)**	**7,094**	**10,139**

1.8 Reimbursement of leasehold improvements of corporate headquarters

6.	**Payments to directors of the entity and their associates**	**Current quarter $'000 USD**
6.1	Aggregate amount of payments to these parties included in item 1.2	69
6.2	Aggregate amount of cash flow from loans to these parties included in item 2.3	—

6.3 Include below any explanation necessary to understand the transactions included in items 6.1 and 6.2

Australian Director fees (1 non-executive director)	USD $14
U.S. Director fees (5 non-executive directors)	USD $55

7.	**Payments to related entities of the entity and their associates**	**Current quarter $'000 USD**
7.1	Aggregate amount of payments to these parties included in item 1.2	—
7.2	Aggregate amount of cash flow from loans to these parties included in item 2.3	—

7.3 Include below any explanation necessary to understand the transactions included in items 7.1 and 7.2

8.	**Financing facilities available** *Add notes as necessary for an understanding of the position*	**Total facility amount at quarter end $'000 USD**	**Amount drawn at quarter end $'000 USD**
8.1	Loan facilities	—	—
8.2	Credit standby arrangements	—	—
8.3	Other (please specify)	—	—

8.4 Include below a description of each facility above, including the lender, interest rate and whether it is secured or unsecured. If any additional facilities have been entered into or are proposed to be entered into after quarter end, include details of those facilities as well.

9.	**Estimated cash outflows for next quarter**	**$'000 USD**
9.1	Research and development	750
9.2	Product manufacturing and operating costs	350
9.3	Advertising and marketing	50
9.4	Leased assets	—
9.5	Staff costs	2,050
9.6	Administration and corporate costs	750
9.7	Other	—
9.8	**Total estimated cash outflows**	**3,950**

10.	**Acquisitions and disposals of business entities** (items 2.1(b) and 2.2(b) above)	**Acquisitions**	**Disposals**
10.1	Name of entity	N/A	N/A
10.2	Place of incorporation or registration		
10.3	Consideration for acquisition or disposal		
10.4	Total net assets		
10.5	Nature of business		

Compliance statement

1 This statement has been prepared in accordance with accounting standards and policies which comply with Listing Rule 19.11A.

2 This statement gives a true and fair view of the matters disclosed.

Sign here: */s/ Brandi L. Roberts* Date: 29 October 2018
(Director/Company secretary)

Print name: Brandi L. Roberts

Notes

1. The quarterly report provides a basis for informing the market how the entity's activities have been financed for the past quarter and the effect on its cash position. An entity that wishes to disclose additional information is encouraged to do so, in a note or notes included in or attached to this report.

2. If this quarterly report has been prepared in accordance with Australian Accounting Standards, the definitions in, and provisions of, *AASB 107: Statement of Cash Flows* apply to this report. If this quarterly report has been prepared in accordance with other accounting standards agreed by ASX pursuant to Listing Rule 19.11A, the corresponding equivalent standard applies to this report.

3. Dividends received may be classified either as cash flows from operating activities or cash flows from investing activities, depending on the accounting policy of the entity.